Crescendo Touts Rheumatoid Arthritis Dx Data Haul At ACR2016

18 Nov 2016

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, is talking-up the results of four different clinical trials of its Vectra DA multi-analyte blood test for rheumatoid arthritis that were presented at this year's American College of Rheumatology meeting in Washington, DC.

Crescendo Bioscience Inc. has received a boost from new clinical data that supports the use of its Vectra DA multi-analyte blood test to predict the progression of rheumatoid arthritis (RA) and suggest it can help physicians make better treatment choices for RA patients.

Crescendo, a subsidiary of Myriad Genetics Inc. based in South San Francisco, developed Vectra DA based on its MultiBiomarker...